R2 Technology files suit against CADx:
This article was originally published in Clinica
Executive Summary
R2 Technology of Sunnyvale, California, has filed a patent infringement suit against Shire Pharmaceuticals subsidiary CADx Medical Systems of Laval, Quebec, CADx Systems of Northborough, Massachusetts, and Qualia Computing of Beavercreek, Ohio. It claims that the defendants' Second Look breast cancer detection system infringes three of its patents covering techniques for scanning, processing and displaying images. R2 markets the ImageChecker computer-aided diagnosis system for screening, diagnostic and digital mammography. "All Second Look technology was researched, developed and patented by CADx scientists," said CADx CEO Steve Rogers. CADx claims to have published its first work in CAD mammography 26 years before R2's patents.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.